Madrigal Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 276
- Market Cap
- $5.5B
- Introduction
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
- Conditions
- Renal Impairment
- Interventions
- Drug: 100 mg Resmetirom Tablet
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06397872
- Locations
- πΊπΈ
Madrigal Research Center, Chicago, Illinois, United States
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
- Conditions
- NASHCirrhosis, Liver
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05500222
- Locations
- πΊπΈ
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
πΊπΈArizona Liver Health - Chandler, Chandler, Arizona, United States
πΊπΈArizona Liver Health - Peoria, Peoria, Arizona, United States
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT04951219
- Locations
- πΊπΈ
Miami Dade Medical Research Institute, Miami, Florida, United States
πΊπΈPlatinum - Sterling Research Group - Springdale, Cincinnati, Ohio, United States
πΊπΈTexas Liver Institute/American Research Corporation, San Antonio, Texas, United States
Drug Interaction Study of MGL-3196 With Clopidogrel
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04671069
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
Drug Interaction Study of MGL-3196 With Pioglitazone
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04671056
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
- Conditions
- NASH - Nonalcoholic SteatohepatitisHepatic ImpairmentCirrhosis, Liver
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04643795
- Locations
- πΊπΈ
Madrigal Research Center, San Antonio, Texas, United States
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 1343
- Registration Number
- NCT04197479
- Locations
- πΊπΈ
Northwestern Memorial Physicians Group, Chicago, Illinois, United States
πΊπΈFloridian Clinical Research, Hialeah, Florida, United States
πΊπΈDallas Research Center, Dallas, Texas, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 1759
- Registration Number
- NCT03900429
- Locations
- π¨π¦
Toronto Liver Center, Toronto, Ontario, Canada
πΊπΈFlorida Research Institute, Lakewood Ranch, Florida, United States
πΊπΈGI Specialists of Georgia, Marietta, Georgia, United States
Bioavailability Study of MGL-3196 Tablets Compared to Capsules
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03413124
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03220165
- Locations
- πΊπΈ
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States